HCWB HCW Biologics Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001828673
AI RATING
STRONG_SELL
98% Confidence

Investment Thesis

HCW Biologics is in acute financial distress with essentially zero revenue ($54.2K), unsustainable cash burn of $13.4M annually, and only $2M in remaining cash providing approximately 1-2 months of runway. The current ratio of 0.11x indicates severe liquidity crisis and imminent solvency risk.

Strengths

  • + Zero long-term debt reduces leverage risk
  • + Net loss improved 64.3% YoY indicating cost reduction efforts
  • + Gross margin of 20% suggests potential profitability if revenue materializes

Risks

  • ! Revenue collapsed 97.9% YoY to only $54.2K, indicating commercial failure or operations suspension
  • ! Current ratio of 0.11x signals critical liquidity crisis and potential insolvency within weeks
  • ! Annual operating cash burn of $13.4M against $2M cash balance indicates bankruptcy risk without immediate financing
  • ! Shareholder equity of $2.8M represents minimal buffer; dilution evident from -$10.63 EPS
  • ! Zero insider Form 4 filings in 90 days suggests management has no confidence in recovery

Key Metrics to Watch

Financial Metrics

Revenue
54.2K
Net Income
-8.0M
EPS (Diluted)
$-10.63
Free Cash Flow
-13.4M
Total Assets
24.5M
Cash
2.0M

Profitability Ratios

Gross Margin 20.0%
Operating Margin -24,270.7%
Net Margin -14,677.1%
ROE -287.9%
ROA -32.5%
FCF Margin -24,693.2%

Balance Sheet & Liquidity

Current Ratio
0.11x
Quick Ratio
0.11x
Debt/Equity
0.00x
Debt/Assets
88.7%
Interest Coverage
-15.58x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-11T02:12:24.881414 | Data as of: 2025-12-31 | Powered by Claude AI